Soonchunhyang Med Sci.
2012 Jun;18(1):26-31.
Efficacy of Intravenous Immunoglobulin Therapy in Childhood Atopic Dermatitis
- Affiliations
-
- 1Department of Pediatrics, Soonchunhyang University College of Medicine, Cheonan, Korea. pjstable@schmc.ac.kr
- 2Department of Preventive Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
- 3Department of Laboratory Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea.
- 4Department of Clinical Parasitology, Soonchunhyang University College of Medicine, Cheonan, Korea.
Abstract
OBJECTIVE
Atopic dermatitis (AD) is a chronic inflammatory skin disease with significant morbidity, and for which there is a need for safe and effective alternative therapies. Although a few observations on the efficacy of intravenous immunoglobulin (IVIG) in AD have been reported, clinical evidence of effectiveness from controlled trials is lacking. Therefore, the purpose of this study was to clarify whether IVIG therapy (1.0 g/kg body weight at each monthly visit for 6 months) is effective in childhood atopic dermatitis and to analyze the clinical characteristics of IVIG responses in this disease.
METHODS
Forty three atopic dermatitis patients who had characteristic clinical features of atopic dermatitis were included in this study. The patients received an injection of IVIG at 1.0 g/kg body weight at each monthly visit for 6 months. Laboratory tests were performed for blood chemistry, total immunoglobulin E, immunoglobulin G/immunoglobulin A/immunoglobulin M, blood eosinophil count, and C-reactive protein.
RESULTS
In total forty three atopic dermatitis patients, only 14 patients completely underwent 6 cycles, but other 29 patients incompletely (1-5 cycles). In the 14 patients, there were just 13 records of scoring atopic dermatitis (SCORAD) index. The mean SCORAD score in the 13 patients was 39.6+/-24.4. SCORAD score decreased significantly (initial SCORAD, 39.6+/-24.4; final SCORAD, 21.3+/-15.6; P=0.016).
CONCLUSION
IVIG therapy may be recommended in the treatment of recalcitrant atopic dermatitis. In addition, further investigation on predictive markers for responses of IVIG therapy in atopic dermatitis may be needed.